Freedom Capital has upgraded its rating on Johnson & Johnson (J&J) from 'hold' to 'buy' following a stronger-than-expected quarterly earnings report. The US healthcare giant posted revenue that exceeded analyst forecasts, driven by robust sales in its medical devices division and prescription drug portfolio. The upgrade sent J&J shares up 1.8% in pre-market trading in New York, providing a lift to the broader healthcare sector.
The positive read-across was felt in London, where the FTSE 100 edged 0.3% higher to 8,215 points by mid-morning, with pharmaceutical stocks among the top gainers. GSK rose 0.7% to 1,542p, while AstraZeneca added 0.5% to 12,876p. The FTSE 250 also gained 0.2%, supported by mid-cap healthcare names. Analysts at Freedom Capital noted that J&J's diversified business model and strong pipeline give it resilience in a volatile macro environment.
Context: The upgrade comes at a time when global pharmaceutical stocks have faced headwinds from patent expiries and pricing pressures. J&J's quarterly beat, however, has reassured investors that large-cap pharma can still deliver growth through innovation and cost discipline. For UK investors, the sector represents a significant weighting in pension funds and income-focused portfolios, with many FTSE 100 healthcare names offering attractive dividend yields.
Sector context: The healthcare sector has been a relative outperformer this year, with the FTSE 350 Pharmaceuticals & Biotechnology index up 6% year-to-date. Analysts at Shore Capital commented that the J&J upgrade 'reinforces confidence in the defensive qualities of large-cap pharma, particularly during periods of economic uncertainty.' They added that UK-listed peers could benefit from similar tailwinds, though individual stock performance will depend on pipeline execution.
Implications for UK investors: While the upgrade is US-centric, the interconnected nature of global healthcare markets means that positive sentiment often spills over. UK pension holders with exposure to index-tracking funds will see a modest benefit from any sustained rally in pharmaceutical stocks. However, investors should be aware that currency fluctuations between the dollar and sterling can affect returns on US-listed holdings.